Sven-Erik Strand

List of Publications by Year
in descending order

52 papers	764 citations	516710 16 h-index	580821 25 g-index
54 all docs	54 docs citations	54 times ranked	1000 citing authors

#	Article	IF	Citations
1	Hematological Toxicity in Mice after High Activity Injections of 177Lu-PSMA-617. Pharmaceutics, 2022, 14, 731.	4.5	4
2	PSA-Targeted Alpha-, Beta-, and Positron-Emitting Immunotheranostics in Murine Prostate Cancer Models and Nonhuman Primates. Clinical Cancer Research, 2021, 27, 2050-2060.	7.0	13
3	177Lu-PSMA-617 Therapy in Mice, with or without the Antioxidant Î±1-Microglobulin (A1M), Including Kidney Damage Assessment Using 99mTc-MAG3 Imaging. Biomolecules, 2021, 11, 263.	4.0	10
4	A Conjugation Strategy to Modulate Antigen Binding and FcRn Interaction Leads to Improved Tumor Targeting and Radioimmunotherapy Efficacy with an Antibody Targeting Prostate-Specific Antigen. Cancers, 2021, 13, 3469.	3.7	5
5	Kidney Protection with the Radical Scavenger Î±1-Microglobulin (A1M) during Peptide Receptor Radionuclide and Radioligand Therapy. Antioxidants, 2021, 10, 1271.	5.1	5
6	Humanization, Radiolabeling and Biodistribution Studies of an IgG1-Type Antibody Targeting Uncomplexed PSA for Theranostic Applications. Pharmaceuticals, 2021, 14, 1251.	3.8	0
7	Genetic signature of prostate cancer mouse models resistant to optimized hK2 targeted Î±-particle therapy. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 15172-15181.	7.1	16
8	Quantitative Î³-H2AX immunofluorescence method for DNA double-strand break analysis in testis and liver after intravenous administration of 111InCl3. EJNMMI Research, 2020, 10, 22.	2.5	15
9	Protection of Kidney Function with Human Antioxidation Protein Î±₁-Microglobulin in a Mouse ¹⁷⁷Lu-DOTATATE Radiation Therapy Model. Antioxidants and Redox Signaling, 2019, 30, 1746-1759.	5.4	22
10	Preclinical efficacy of hK2 targeted [¹⁷⁷Lu]hu11B6 for prostate cancer theranostics. Theranostics, 2019, 9, 2129-2142.	10.0	17
11	Preserving Preclinical PET Quality During Intratherapeutic Imaging in Radionuclide Therapy with Rose Metal Shielding Reducing Photon Flux. Journal of Nuclear Medicine, 2019, 60, 710-715.	5.0	0
12	Harnessing Androgen Receptor Pathway Activation for Targeted Alpha Particle Radioimmunotherapy of Breast Cancer. Clinical Cancer Research, 2019, 25, 881-891.	7.0	21
13	An aggressive RhoC phenotype is associated with relapse after external beam radiation therapy of a prostate cancer xenograft model.. Journal of Clinical Oncology, 2019, 37, e14748-e14748.	1.6	0
14	Feed-forward alpha particle radiotherapy ablates androgen receptor-addicted prostate cancer. Nature Communications, 2018, 9, 1629.	12.8	37
15	Simultaneous Preclinical Positron Emission Tomography-Magnetic Resonance Imaging Study of Lymphatic Drainage of Chelator-Free ⁶⁴Cu-Labeled Nanoparticles. Cancer Biotherapy and Radiopharmaceuticals, 2018, 33, 213-220.	1.0	13
16	Combined Magnetomotive ultrasound, PET/CT, and MR imaging of 68Ga-labelled superparamagnetic iron oxide nanoparticles in rat sentinel lymph nodes in vivo. Scientific Reports, 2017, 7, 4824.	3.3	62
17	High resolution digital autoradiographic and dosimetric analysis of heterogeneous radioactivity distribution in xenografted prostate tumors. Medical Physics, 2016, 43, 6632-6643.	3.0	3
18	Internalization of secreted antigenâ€“targeted antibodies by the neonatal Fc receptor for precision imaging of the androgen receptor axis. Science Translational Medicine, 2016, 8, 367ra167.	12.4	23

#	Article	IF	Citations
19	Counting Rate Characteristics and Image Distortion in Preclinical PET Imaging During Radiopharmaceutical Therapy. Journal of Nuclear Medicine, 2016, 57, 1964-1970.	5.0	2
20	An attenuation method for reducing count rate losses in preclinical PET during intratherapeutic imaging. , 2016, , .		0
21	Radioimmunotherapy for Prostate Cancerâ€"Current Status and Future Possibilities. Seminars in Nuclear Medicine, 2016, 46, 165-179.	4.6	23
22	Radiosensitivity of Prostate Cancer Cell Lines for Irradiation from Beta Particle-emitting Radionuclide Â¹â•Lu Compared to Alpha Particles and Gamma Rays. Anticancer Research, 2016, 36, 103-9.	1.1	8
23	Characterization of a doubleâ€sided silicon strip detector autoradiography system. Medical Physics, 2015, 42, 575-584.	3.0	6
24	Using Rose's metal alloy as a pinhole collimator material in preclinical smallâ€animal imaging: A Monte Carlo evaluation. Medical Physics, 2015, 42, 1698-1709.	3.0	5
25	Size-dependent lymphatic uptake of nanoscale-tailored particles as tumor mass increases. Future Science OA, 2015, 1, FSO60.	1.9	2
26	Human Anti-Oxidation Protein A1Mâ€"A Potential Kidney Protection Agent in Peptide Receptor Radionuclide Therapy. International Journal of Molecular Sciences, 2015, 16, 30309-30320.	4.1	12
27	Radiolabeled antibodies in prostate cancer: A case study showing the effect of host immunity on antibody bio-distribution. Nuclear Medicine and Biology, 2015, 42, 375-380.	0.6	9
28	Intratherapeutic Biokinetic Measurements, Dosimetry Parameter Estimates, and Monitoring of Treatment Efficacy Using Cerenkov Luminescence Imaging in Preclinical Radionuclide Therapy. Journal of Nuclear Medicine, 2015, 56, 444-449.	5.0	13
29	Superparamagnetic iron oxide nanoparticles as a multimodal contrast agent for up to five imaging modalities. Clinical and Translational Imaging, 2015, 3, 247-249.	2.1	3
30	Cancer Cell Radiobiological Studies Using In-House-Developed Î±-Particle Irradiator. Cancer Biotherapy and Radiopharmaceuticals, 2015, 30, 386-394.	1.0	9
31	Biodistribution and pharmacokinetics of recombinant Î±1-microglobulin and its potential use in radioprotection of kidneys. American Journal of Nuclear Medicine and Molecular Imaging, 2015, 5, 333-47.	1.0	12
32	Preclinical imaging of kallikrein-related peptidase 2 (hK2) in prostate cancer with a 111In-radiolabelled monoclonal antibody, 11B6. EJNMMI Research, 2014, 4, 51.	2.5	20
33	¹⁸⁸Re-Z_{HER2:V2}, a Promising Affibody-Based Targeting Agent Against HER2-Expressing Tumors: Preclinical Assessment. Journal of Nuclear Medicine, 2014, 55, 1842-1848.	5.0	23
34	Development of a Hybrid Nanoprobe for Triple-Modality MR/SPECT/Optical Fluorescence Imaging. Diagnostics, 2014, 4, 13-26.	2.6	5
35	Optimizing retention of multimodal imaging nanostructures in sentinel lymph nodes by nanoscale size tailoring. Nanomedicine: Nanotechnology, Biology, and Medicine, 2014, 10, e1089-e1095.	3.3	25
36	Multi-radionuclide digital autoradiography of the intra-aortic atherosclerotic plaques using a monoclonal antibody targeting oxidized low-density lipoprotein. American Journal of Nuclear Medicine and Molecular Imaging, 2014, 4, 172-80.	1.0	1

#	Article	IF	Citations
37	Preclinical evaluation of (111)In-DTPA-INCA-X anti-Ku70/Ku80 monoclonal antibody in prostate cancer. American Journal of Nuclear Medicine and Molecular Imaging, 2014, 4, 311-23.	1.0	0
38	(68)Ga-labeled superparamagnetic iron oxide nanoparticles (SPIONs) for multi-modality PET/MR/Cherenkov luminescence imaging of sentinel lymph nodes. American Journal of Nuclear Medicine and Molecular Imaging, 2013, 4, 60-9.	1.0	28
39	Use of Monte Carlo simulations with a realistic rat phantom for examining the correlation between hematopoietic system response and red marrow absorbed dose in Brown Norway rats undergoing radionuclide therapy with177Lu- and90Y-BR96 mAbs. Medical Physics, 2012, 39, 4434-4443.	3.0	13
40	The Combination of In vivo 124I-PET and CT Small Animal Imaging for Evaluation of Thyroid Physiology and Dosimetry. Diagnostics, 2012, 2, 10-22.	2.6	6
41	Monte Carlo calculations of absorbed doses in tumours using a modified MOBY mouse phantom for pre-clinical dosimetry studies. Acta OncolÃ³gica, 2011, 50, 973-980.	1.8	30
42	Determining Maximal Tolerable Dose of the Monoclonal Antibody BR96 Labeled with 90Y or 177Lu in Rats: Establishment of a Syngeneic Tumor Model to Evaluate Means to Improve Radioimmunotherapy. Clinical Cancer Research, 2005, 11, 7104s-7108s.	7.0	13
43	The LundADose Method for Planar Image Activity Quantification and Absorbed-Dose Assessment in Radionuclide Therapy. Cancer Biotherapy and Radiopharmaceuticals, 2005, 20, 92-97.	1.0	30
44	Distribution of iodine 125â€“labeled Î±1-microglobulin in rats after intravenous injection. Translational Research, 2001, 137, 165-175.	2.3	46
45	A Monte Carlo Program Converting Activity Distributions to Absorbed Dose Distributions in a Radionuclide Treatment Planning System. Acta OncolÃ³gica, 1996, 35, 367-372.	1.8	40
46	Plasma exudation in the skin measured by external detection of conversion electrons. European Journal of Nuclear Medicine and Molecular Imaging, 1996, 23, 290-294.	2.1	3
47	Parameters Influencing Volume and Activity Quantitation in Spect. Acta OncolÃ³gica, 1996, 35, 323-330.	1.8	11
48	Improving Radioimmonotargeting of Tumors: Variation in the Amount of L6 Mab Administered, Combined with an Immunoadsorption System (Ecia). Acta OncolÃ³gica, 1993, 32, 853-859.	1.8	7
49	Radioimmunotherapy Dosimetryâ€”A Review. Acta OncolÃ³gica, 1993, 32, 807-817.	1.8	31
50	Beta Camera Low Activity Tumor Imaging. Acta OncolÃ³gica, 1993, 32, 869-872.	1.8	6
51	Pharmacokinetic modeling. Medical Physics, 1993, 20, 515-527.	3.0	49
52	Influence of a reticuloendothelial-suppressing agent on liver tumor growth in the rat. Journal of Surgical Oncology, 1984, 26, 245-251.	1.7	7